IBRX ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.7M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Cohen Cheryl | Director | Sell 10b5-1 | 131,210 | $9.50 | $1.2M | 125,386 −51.1% of holding | |
| Selecky Christobel | Director | Sell 10b5-1 | 159,478 | $9.02 | $1.4M | None left | |
| Selecky Christobel | Director | Sell 10b5-1 | 1,000 | $9.00 | $9.0K | None left | |
| Selecky Christobel | Director | Sell 10b5-1 | 95,722 | $9.01 | $862.2K | None left | |
| Simon Barry J. | Director | Sell 10b5-1 | 25,000 | $7.88 | $196.9K | 2,802,788 −0.9% of holding | |
| Simon Barry J. | Director | Sell 10b5-1 | 23,033 | $7.18 | $165.3K | 2,827,788 −0.8% of holding | |
| Simon Barry J. | Director | Sell 10b5-1 | 75,000 | $12.01 | $900.8K | 2,850,821 −2.6% of holding | |
| Simon Barry J. | Director | Sell 10b5-1 | 165,000 | $10.25 | $1.7M | 2,925,821 −5.3% of holding | |
| Selecky Christobel | Director | Sell 10b5-1 | 25,000 | $10.00 | $250.0K | None left | |
| Simon Barry J. | Director | Sell 10b5-1 | 10,000 | $9.25 | $92.5K | 3,081,604 −0.3% of holding | |
| Simon Barry J. 2 fills | Director | Sell 10b5-1 | 151,967 | $7.20 | $1.1M | 3,166,604 −4.6% of holding | |
| Selecky Christobel | Director | Sell 10b5-1 | 25,000 | $7.51 | $187.7K | None left | |
| Selecky Christobel | Director | Sell 10b5-1 | 50,000 | $5.00 | $250.0K | None left |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.